Agendia news and milestones

Podium presentation by Co-Founder and Chief Research Officer Laura van 't Veer introduces an AI-driven approach to MammaPrint Two additional poster presentations from the FLEX St…

Not every woman with early-stage breast cancer needs chemotherapy. Genomic tests like MammaPrint are helping doctors determine who does. When I was diagnosed with Stage IIA breas…

Agendia's landmark FLEX Study reaches a major enrollment milestone, accelerating real-world insights to advance more personalized breast cancer care IRVINE, Calif, and AMSTERDAM…

Every woman who receives a diagnosis of breast cancer is unique and requires a personalized treatment plan. An essential part of this plan is to understand the chance that breast…

For years, a cancer diagnosis often came down to one test, one gene, one mutation. Today, clinical laboratories are adopting broader approaches-including whole-genome sequencing,…

IRVINE, Calif.& AMSTERDAM---- Agendia , Inc., a leader in precision oncology for breast cancer, today announced the official ruling by the Swiss Federal Office of Public Health t…

Hearing the words "you need a biopsy" or "we found something suspicious" during a clinical breast exam, mammogram, or MRI can stop everything in its tracks. Feeling worried or un…

FLEX Study data shows that patients with MammaPrint High Risk 2 tumors have improved 3-year survival with anthracycline-containing regimens, while patients with High Risk 1 tumor…

Publication: JCO Precis Oncol, June 2026 DOI https://doi.org/10.1200/PO-25-01285 Authors: Joyce O'Shaughnessy et al. Title: Prognostic Performance of MammaPrint in Patients with…

Gene expression profiling links HRD in patients with high risk breast cancer with anthracycline outcomes Steven Isakoff, Breast Medical Oncologist at Mass General Brigham Cancer…

Publication: ASCO 2026, Abstract #621 Authors: David Page Title: Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer Abstr…

Publication: ASCO 2026, Abstract #561 Authors: Steve Isakoff Title: Association of the 70-gene assay and homologous recombination deficiency in patients with High Risk 2 breast c…

IRVINE, Calif. & AMSTERDAM, May 01, 2026--Multivariate analyses reveal that pCR is associated with transcriptomic differences and chemotherapy type, rather than self-reported race

MammaPrint is a gene expression profiling test that assesses the risk of distant metastasis in early-stage breast cancer.